Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial
Authors:
- Max YatesMYMax Yates
- Louise E. HamiltonLHLouise E. Hamilton
- Frances ElenderFEFrances Elender
- Loretta DeanLDLoretta Dean
- Helen DollHDHelen Doll
- Alex J. MacGregorAMAlex J. MacGregor
- Joegi ThomasJTJoegi Thomas
- Karl GaffneyKGKarl Gaffney
- 1 June 2015
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 42 (7) , 1177-1185
Abstract
Objective.: To investigate, in a pilot randomized controlled trial, whether etanercept (ETN) 25 mg once weekly is effective at maintaining a clinical response in patients with ankylosing spondylitis (AS) who have responded to the standard 50 mg dose.Methods.: Adults with AS not responding to conventional therapies were prescribed ETN 50 mg once weekly for 6 months. Responders as defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were randomly assigned to taper to 25 mg once weekly or continue on 50 mg and followed for a further 6 months. The primary outcome measure was maintenance of a 50% reduction in the BASDAI or fall in BASDAI by ≥ 2 units and a ≥ 2-unit reduction in BASDAI spinal pain as measured on a 10-point visual analog scale at 6 months postrandomization.Results.: Of 89 patients assessed for eligibility, 59 were enrolled; 47 (80%) had sufficient clinical response and were eligible for randomization, 24 were assigned to continue receiving ETN 50 mg, and 23 to taper to 25 mg. After 6 months, 20 (83%) of the 50 mg arm maintained clinical response compared with 12 (52%) of the 25 mg arm (a difference of −31%, 95% CI −58% – −5%).Conclusion.: Although this pilot study demonstrates that treatment with ETN 25 mg was less effective at maintaining treatment response in the stepdown phase, 52% of participants maintained treatment response. Future research should address which patients are suitable for tapering.Keywords
This publication has 28 references indexed in Scilit:
- Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up studyBiologics: Targets and Therapy, 2013
- Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot StudyMediators of Inflammation, 2013
- Economic Considerations of the Treatment of Ankylosing SpondylitisThe American Journal of the Medical Sciences, 2012
- High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)Rheumatology, 2011
- 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisAnnals of the Rheumatic Diseases, 2011
- Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the diseaseClinical Rheumatology, 2011
- Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysisClinical Rheumatology, 2010
- Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patientsClinical Rheumatology, 2007
- Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based surveyClinical Rheumatology, 2006
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984